The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: Trastuzumab (Herceptin), Paclitaxel, Carboplatin and Gemcitabine in Advanced Urothelial Cancer
Official Title: Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer
Study ID: NCT00151034
Brief Summary: Purpose: The purpose of this study is to evaluate the efficacy and safety of treatment with trastuzumab (Herceptin) along with the three other chemotherapy drugs, paclitaxel, carboplatin and gemcitabine, in patients who have advanced urothelial cancer. This clinical trial will also collect information (alternative therapy, response rates, overall survival) from enrolled patients with HER2 negative tumors who are ineligible to receive study treatment.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
California City of Hope National Medical Group, Duarte, California, United States
USC/Norris Comprehensive Cancer Center, Los Angeles, California, United States
U.C. Davis Medical Center, Sacramento, California, United States
University of Colorado, Aurora, Colorado, United States
The University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, United States
Wayne State University, Detroit, Michigan, United States
Roswell Park Cancer Institute, Buffalo, New York, United States
Columbia Presbyterian Medical Center, New York, New York, United States
Weill Medical College of Cornell University, New York, New York, United States
University of Pennsylvania Cancer Center, Philadelphia, Pennsylvania, United States
University of Pittsburgh Cancer Institute, Pittsburgh, Pennsylvania, United States
Name: Maha Hussain, MD
Affiliation: The University of Michigan Comprehensive Cancer Center
Role: PRINCIPAL_INVESTIGATOR